0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > HSA

HSA

HSA Molecule Information

Name:DNA (cytosine-5)-methyltransferase 1
Target Synonym:DNA methyltransferase HsaI;AIM ;CXXC-type zinc finger protein 9;Dnmt1;DNA (cytosine-5)-methyltransferase 1;DNMT1;MCMT;DNA MTase HsaI;CXXC9;DNMT;M.HsaI
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

HSA Molecule Synonym Name

HSA,ALB,Serum Albumin

HSA Molecule Background

Human serum albumin (HSA) is also known as ALB,which is the main protein of plasma and has a good binding capacity for water,Ca2+,Na+,K+,fatty acids,hormones, bilirubin and drugs.The main function of HSA is the regulation of the colloidal osmotic pressure of blood. As Major zinc transporter in plasma, HSA typically binds about 80% of all plasma zinc.A variant structure of albumin could lead to increased binding of zinc resulting in an asymptomatic augmentation of zinc concentration in the blood. Defects in serum albumin can cause familial dysalbuminemic hyperthyroxinemia which is a form of euthyroid hyperthyroxinemia that is due to increased affinity of serum albumin for T4.It is the most common cause of inherited euthyroid hyperthyroxinemia in Caucasian population.

HSA References

HSA Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Triclabendazole CGA-89317; EGA-230B; NVP-EGA230 Approved Novartis EGATEN fda NOVARTIS 2019-02-13 Hepatic fascioliasis Details
Decitabine NSC-127716; 5-aza-CdR; AzadC; DAC; E-7373 Approved Eisai, Otsuka DACOGEN fda Myelodysplastic syndrome (MDS) OTSUKA PHARM CO LTD 2006-05-02 Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML), Chronic myeloid leukemia (CML ) Details
Azacitidine NS-17; 5-aza-CR; CC-486; NSC-102816; U-18496,NS 17,NS17 Approved Celgene, BeiGene VIDAZA fda Myelodysplastic syndrome (MDS) CELGENE 2004-05-19 Myelodysplastic syndrome (MDS) Details

HSA Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Azacitidine/Lenalidomide Phase Ⅱ Celgene Acute myeloid Leukemia (AML) Details
Aza-T-dCyd Aza-T-dCyd Phase Not Specified Southern Research Institute Cancer Details
Guadecitabine Sodium SGI-110; S-110; 0RB89YH367 (UNII code)  Phase Ⅲ Otsuka Myelodysplastic syndrome (MDS), Chronic myelomonocytic leukemia(CMML), Acute myeloid Leukemia (AML) Details
Decitabine/Tetrahydrouridine EPI-01 Phase Ⅰ EpicDestiny, Novo Nordisk Sickle cell disease Details
Fluorocyclopentenylcytosine TV-1360; RX-3117; FCPEC,TV1360,RX3117 Phase Ⅱ Rexahn Pharmaceuticals Bladder cancer, Pancreatic cancer Details
MG-98 MG-98,MG 98,MG98 Phase Ⅱ Mirati Therapeutics, Mgi Pharma Myelodysplastic syndrome (MDS), Solid tumours, Acute myeloid Leukemia (AML), Renal carcinoma, Head and neck cancer Details
Decitabine/Gemcitabine Preclinical University of Minnesota HIV infection Details
Cedazuridine/Decitabine ASTX-727; Decitabine/E7727; E-7727/decitabine Phase Ⅲ Astex Pharmaceuticals Myelodysplastic syndrome (MDS), Chronic myeloid leukemia (CML ) Details
TdCyd TdCyd; T-dcyd Phase Ⅰ National Cancer Institute Solid tumours Details
FdCyd NSC-48006; Ro-5-1090,NSC48006; Ro5-1090 Phase Ⅱ City of Hope National Medical Center, National Cancer Institute Solid tumours Details

This web search service is supported by Google Inc.

totop